Observational study of the additive effects of pranlukast on inflammatory markers of clinically stable asthma with inhaled corticosteroids and long-acting beta 2 agonists

Respiration

Volumn 76, Issue 4, 2008, Pages 398-402

  Tomari, Shinya ^a   Matsuse, Hiroto ^c   Hirose, Hiroko ^c   Tsuchida, Tomoko ^c   Fukahori, Susumu ^c   Fukushima, Chizu ^c   Kawano, Tetsuya ^b   Matsuo, Nobuko ^d   Kohno, Shigeru ^c  

^a Sasebo Shiritsu Sogo Hospital   (Japan)

^b Senju Hospital   (Japan)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

Additive therapy; Airway inflammation; Asthma; Inhaled corticosteroid; Leukotriene receptor antagonist; Long acting 2 agonist

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 5; PEPTIDOLEUKOTRIENE; PRANLUKAST; SALMETEROL; SALMETEROL XINAFOATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CLINICAL ARTICLE; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; EOSINOPHIL COUNT; FEMALE; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SPUTUM ANALYSIS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL MARKERS; CHROMONES; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPUTUM;

EID: 56649094467     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151289     Document Type: Article

References (31)

1. Busse WW, Lemanske RF Jr: Asthma. N Engl J Med 2001;344:350-362.
2. Global Initiative for Asthma: GINA report, global strategy for asthma management and prevention: Bethesda, Maryland, USA, National Institutes of Health, National Heart, Lung, and Blood Institute, 2006.
3. Doucet MY, Jones TR, Ford-Hutchinson AW: Responses of equine trachealis and lung parenchyma to methacholine, histamine, serotonin, prostanoid, and leukotrienes in vitro. Can J Physiol Pharmacol 1990;68:379-383.
4. Busse W, Kraft M: Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127:1312-1326.
5. Taniguchi Y, Tamura G, Honma M, Aizawa T, Maruyama N, Shirato K, et al: The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993;25:131-142.
6. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, et al: Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997;155:1235-1240.
7. Tomari S, Shimoda T, Kawano T, Mitsuta K, Obase Y, Fukushima C, et al: Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol 2001;87:156-161.
8. Obase Y, Shimoda T, Matsuse H, Kondo Y, Machida I, Kawano T, et al: The position of pranlukast, a cysteinyl leukotriene receptor antagonist, in the long-term treatment of asthma: 5-year follow-up study. Respiration 2004;71:225-232.
9. Tomari S, Matsuse H, Machida I, Kondo Y, Kawano T, Obase Y, et al: Pranlukast, a cysteinyl leukotriene 1 receptor antagonist, attenuates allergen-specific tumor necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics. Clin Exp Allergy 2003;33:795-801.
10. Fukushima C, Matsuse H, Hishikawa Y, Kondo Y, Machida I, Saeki S, et al: Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism. Int Arch Allergy Immunol 2005;136:165-172.
11. Matsuse H, Kondo Y, Machida I, Kawano T, Saeki S, Tomari S, et al: Effects of anti-inflammatory therapies on recurrent and lowgrade respiratory syncytial virus infections in a murine model of asthma. Ann Allergy Asthma Immunol 2006;97:55-60.
12. Currie GP, Lee DK, Srivastava P: Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest 2005;128:2954-2962.
13. Heaney LG, Robinson DS: Severe asthma treatment: need for characterizing patients. Lancet 2005;365:974-976.
14. Dupont L, Potvin E, Korn D, Lachman A, Dramaix M, Gusman J, et al: Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study. Curr Med Res Opin 2005;21:863-869.
15. 4 and inhibits aspirin-induced asthma to threshold dose of aspirin. J Allergy Clin Immunol 2004;114:1278-1281.
16. Shah AR, Sharples LD, Solanki RN, Shah KV: Double-blind, randomized, controlled trial assessing controller medications in asthma. Respiration 2006;73:449-456.
17. Shah L, Wilson AJ, Gibson PG, Coughlan J: Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2003;(3):CD001281.
18. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela ST, et al: Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomized, comparative trial. BMJ 2003;327:891-895.
19. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, et al: Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004;92:641-648.
20. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ: Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003;167:1232-1238.
21. Biernacki WA, Kharitonov SA, Biernacka HM, Barnes PJ: Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients. Chest 2005;128:1958-1963.
22. Mondino C, Ciabattoni G, Koch P, Pistelli R, Trove A, Barnes PJ, et al: Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J Allergy Clin Immunol 2004;4:761-767.
23. Robinson DS, Campbell D, Barnes PJ: Addition of leukotriene receptor antagonists to therapy in chronic persistent asthma: a randomized double blind placebo-controlled trial. Lancet 2001;357:2007-2011.
24. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, et al: Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005;128:1910-1920.
25. 2-agonists, and leukotriene modifiers in asthma. Chest 2006;130:301-302.
26. Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, et al: Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997;99:1767-1773.
27. Pang L, Knox AJ: Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. FASEB J 2001;15:261-269.
28. Ram FS, Cates CJ, Ducharme FM: Long-acting beta2-agonist versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005;(1):CD003137.
29. American Lung Association Asthma Clinical Research Centers, Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, et al: Randomised comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007;356:2027-2039.
30. Leigh R, Vethanayagam D, Yoshida M, Watson RM, Rerecich T, Inman MD, et al: Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 2002;166:1212-1217.
31. Henderson WR Jr, Chiang GK, Tien YT, Chi EY: Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006;173:718-728.